## APPENDIX 3 - TABLES OF CIN 2 AND CIN 3 CASES ASSOCIATED WITH NON-VACCINE HPV TYPES 31, 33, 35, 39, 45, 51, 52, 56, 58, AND 59 IN SUBJECTS NAÏVE (PCR NEGATIVE) FOR THE SPECIFIC NON-VACCINE HPV TYPE AT BASELINE.

CIN 3 and CIN 2 Cases associated with Non-Vaccine HPV type 31 and
P- at baseline for relevant HPV types (Close-out of Studies HPV-013 and HPV-015)

| CIN 3 | $\begin{aligned} & \hline \text { Gardasil } \\ & \mathrm{N}=2717 \\ & \text { (013) } \\ & \mathrm{N}=6082 \\ & \text { (015) } \\ & \text { Total = } \\ & 8799 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total = 8800 } \end{aligned}$ | CIN 2 | Gardasil $\mathrm{N}=2717$ $(013)$ $\mathrm{N}=6082$ (015) Total $=8799$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total = 8800 } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HPV 31 | 15 | 32 (8 also naïve for Vax HPV) | HPV 31 Total | 8 | 21 (5 also naïve for Vax HPV) |
| 31 alone | 7 | 14 | 31 alone | 7 | 7 |
| 31, 6 | 0 | 1 | 31, 6, 16, 39 | 0 | 1 |
| 31, 6, 33, 35 | 0 | 1 | 31, 16 | 0 | 1 |
| 31, 16 | 1 | 2 (2 naïve 16) | 31, 16, 18, 56, 58 | 0 | 1 |
| 31, 16, 18 | 0 | 1 | 31, 16, 33, 45, 58 | 0 | 1 |
| 31, 16, 33, 58 | 0 | 1 | 31, 18, 51 | 0 | 1 |
| 31, 16, 39, 51 | 0 | 1 | 31, 35 | 0 | 1 |
| 31, 16, 51, 52 | 0 | 2 (1 naïve 16) | 31, 45, 51 | 0 | 1 |
| 31, 16, 56, 58, 59 | 0 | 1 | 31, 51, 58 | 1 | 0 |
| 31, 18, 45 | 0 | 1 | 31, 51, 59 | 0 | 1 |
| 31, 18, 51, 58 | 0 | 1 | 31, 52 | 0 | 3 |
| 31, 33 | 2 | 0 | 31;52 | 0 | 1 |
| 31, 35 | 0 | 1 | 31, 56 | 0 | 1 |
| 31, 39 | 0 | 1 | 31, 59 | 0 | 1 |
| 31, 51 | 0 | 1 |  |  |  |
| 31, 51, 52 | 0 | 1 |  |  |  |
| 31, 51, 58 | 1 | 0 |  |  |  |
| 31, 52 | 1 | 1 |  |  |  |
| 31, 52, 56 | 1 | 0 |  |  |  |
| 31, 52, 58 | 0 | 1 |  |  |  |
| 31, 52, 59 | 1 | 0 |  |  |  |
| 31, 56, 58 | 1 | 0 |  |  |  |

HPV types in italics represent $P$-for the relevant non-vaccine HPV type and other HPV types
Case may appear in more than one table for both CIN 2 and CIN 3 cases.

## CIN 3 and CIN 2 Cases associated with Non-Vaccine HPV type 33 and P- at baseline for relevant HPV types (Close-out Data for Studies HPV-013 and HPV-015)

| CIN 3 | Gardasil <br> $\mathrm{N}=2717$ <br> (013) <br> $\mathrm{N}=6082$ <br> (015) <br> Total $=8799$ | $\begin{aligned} & \hline \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total }=8800 \end{aligned}$ | CIN 2 | $\begin{aligned} & \hline \text { Gardasil } \\ & \mathrm{N}=2717(013) \\ & \mathrm{N}=6082(015) \\ & \text { Total }=8799 \end{aligned}$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total = } 8800 \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HPV 33 Total | 18 | 19 (8 also naïve for Vax HPV) | HPV 33 Total | 15 | 14 (2 also naïve for Vax HPV) |
| 33 alone | 8 | 5 | 33 alone | 6 | 6 |
| 33, 6 | 0 | 1 | 33, 16 | 0 | 1 |
| 33, 6, 16 | 0 | 1 | 33, 16, 31, 45, | 0 | 1 |
| 33, 6, 31, 35 | 0 | 1 | 58 |  |  |
| 33, 16 | 0 | 2 | 33, 16, 39, 51, | 0 | 1 |
| 33, 16, 18 | 0 | 2 | 52 |  |  |
| 33, 16, 39 | 1 | 0 | 33, 18, 56 | 0 | 1 |
| 33, 16, 31, 58 | 0 | 1 | 33, 35 | 0 | 1 |
| 33, 16, 51, 56 | 0 | 1 | 33, 39 | 1 | 1 |
| 33, 16, 52 | 0 | 1 | 33, 39, 45, 52 | 0 | 1 |
| 33, 18 | 0 | 1 | 33, 51, 52 | 1 | 0 |
| 33, 31 | 2 | 0 | 33, [52] ,56 | 1 | 0 |
| 33, 31, 51, 56 | 1 | 0 | 33, 56 | 5 | 1 |
| 33, 35 | 1 | 0 | 33, 58 | 1 | 0 |
| 33, 39 | 0 | 1 |  |  |  |
| 33, 39, 59 | 0 | 1 |  |  |  |
| 33, 51, 56 | 1 | 0 |  |  |  |
| 33, 52 | 1 | 0 |  |  |  |
| 33, 56 | 2 | 0 |  |  |  |
| 33, 56, 58 | 0 | 1 |  |  |  |
| 33, 59 | 1 | 0 |  |  |  |

CIN 3 and CIN 2 Cases associated with Non-Vaccine HPV type 35 and $P$ - at baseline for relevant HPV types (Close-out Data for Studies HPV-013 and HPV-015)

| CIN 3 | $\begin{aligned} & \text { Gardasil } \\ & \mathrm{N}=2717(013) \\ & \mathrm{N}=6082(015) \\ & \text { Total = } 8799 \end{aligned}$ | Control $\mathrm{N}=2725(013)$ $\mathrm{N}=6075(015)$ Total $=8800$ | CIN 2 | Gardasil $\mathrm{N}=2717$ $(013)$ $\mathrm{N}=6082$ (015) Total $=8799$ | Control $\mathrm{N}=2725$ (013) $\mathrm{N}=6075(015)$ Total $=8800$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HPV 35 Total | 10 | 5 (1 also naïve for Vax HPV) | HPV 35 Total | 4 | 11 (3 also naïve for Vax HPV) |
| 35 alone | 4 | 2 | 35 alone | 2 | 6 |
| 35, 6, 18, 45, 51, 52, | 0 | 1 | 35, 16 | 0 | 1 |
| 56 |  |  | 35, 16, 39 | 0 | 1 |
| 35, 6, 31, 33 | 0 | 1 | 35, 16, 51 | 0 | 1 |
| 35, 16 | 1 | 0 | 35, 31 | 0 | 1 |
| 35, 31 | 0 | 1 | 35, 31, 39, 52 | 1 | 0 |
| 35, 33 | 1 | 0 | 35, 33 | 0 | 1 |
| 35, 45 | 1 | 0 | 35, 39, 56 | 1 | 0 |
| 35, 51 | 2 (1 naïve <br> 51) | 0 |  |  |  |
| 35,52 | 1 | 0 |  |  |  |

HPV types in italics represent $P$ - for the relevant non-vaccine HPV type and other HPV types
Case may appear in more than one table for both CIN 2 and CIN 3 cases.

CIN 3 and CIN 2 Cases associated with Non-Vaccine HPV type 39 and $P$ - at baseline for relevant HPV types (Close-out Data for Studies HPV-013 and HPV-015)

| CIN 3 | $\begin{aligned} & \text { Gardasil } \\ & \mathrm{N}=2717 \\ & \text { (013) } \\ & \mathrm{N}=6082 \\ & \text { (015) } \\ & \text { Total = } \\ & 8799 \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total }=8800 \end{aligned}$ | CIN 2 | Gardasil $\mathrm{N}=2717$ $(013)$ $\mathrm{N}=6082$ (015) Total $=8799$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total }=8800 \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HPV 39 Total | 5 | 12 (1 also naïve for Vax HPV) | HPV 39 Total | 9 | 14 (5 also naïve for Vax HPV) |
| 39 alone | 1 | 0 | 39 alone | 4 | 3 |
| 39, 6, 16, 58 | 0 | 1 | 39, 6 | 0 | 1 |
| 39, 16 | 0 | 3 | 39, 6, 16, 31 | 0 | 1 |
| 39, 16, 31, 51 | 0 | 1 | 39, 16 | 0 | 1 |
| 39, 16, 33 | 1 | 0 | 39, 16, 33, 51, | 0 | 1 |
| 39, 16, 52, 58 | 1 | 0 | 52 |  |  |
| 39, 31 | 0 | 1 | 39, 16, 35 | 0 | 1 |
| 39, 31, 52 | 0 | 1 | 39, 18, 52 | 0 | 1 |
| 39, 33 | 0 | 1 | 39, 33 | 1 | 1 |
| 39, 33, 45, 52 | 0 | 1 | 39, 33, 45, 52 | 0 | 1 |
| 39, 33, 59 | 0 | 1 | 39, 35, 56 | 1 | 0 |
| 39, 45 | 1 | 0 | 39, 51, 52 | 1 | 0 |
| 39, 45, 52 | 0 | 1 | 39, 52 | 0 | 1 |
| 39, 52 | 0 | 1 | 39, 52, 56 | 0 | 1 |
| 39, 56 | 1 | 0 | $\begin{aligned} & 39,56 \\ & 39,58 \end{aligned}$ | 1 | 0 1 |

HPV types in italics represent P-for the relevant non-vaccine HPV type and other HPV types Case may appear in more than one table for both CIN 2 and CIN 3 cases.

CIN 3 and CIN 2 Cases associated with Non-Vaccine HPV type 45 and $P$ - at baseline for relevant HPV types (Close-out Data for Studies HPV-013 and HPV-015)

| CIN 3 | Gardasil $\mathrm{N}=2717$ $(013)$ $\mathrm{N}=6082$ (015) Total $=8799$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total }=8800 \end{aligned}$ | CIN 2 | $\begin{aligned} & \text { Gardasil } \\ & \mathrm{N}=2717(013) \\ & \mathrm{N}=6082(015) \\ & \text { Total = } 8799 \end{aligned}$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total }=8800 \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HPV 45 Total | 10 | 8 (4 also naïve for Vax HPV) | HPV 45 Total | 2 | 5 (2 also naïve for Vax HPV) |
| 45 alone | 3 | 1 | 45 alone | 1 | 0 |
| 45, 16 | 2 | 1 (naïve for 16) | 45, 16 | 0 | 1 |
| 45, 16, 18, 31 | 0 | 1 | 45, 16, 18, 51, | 0 | 1 |
| 45, 16, 52 | 1 | 1 (naïve for 16 and 52) | $\begin{aligned} & 52 \\ & 45,16,31,33, \end{aligned}$ | 0 | 1 |
| 45, 16, 58 | 1 | 0 | 58 |  |  |
| 45, 18, 31 | 0 | 1 | 45, 31, 51 | 0 | 1 |
| 45, 33, 39, 52 | 0 | 1 | 45, 33, 39, 52 | 0 | 1 |
| 45, 35 | 1 | 0 | 45, 52, 56, 58 | 1 | 0 |
| 45, 39 | 1 | 0 |  |  |  |
| 45, 51,52 | 0 | 1 |  |  |  |
| 45, 51, 56 | 0 | 1 |  |  |  |
| 45, 56 | 1 | 0 |  |  |  |

HPV types in italics represent P-for the relevant non-vaccine HPV type and other HPV types
Case may appear in more than one table for both CIN 2 and CIN 3 cases.

CIN 3 and CIN 2 Cases associated with Non-Vaccine HPV type 51 and P- at baseline for relevant HPV types (Close-out Data for Studies HPV-013 and HPV-015)

| CIN 3 | $\begin{aligned} & \hline \text { Gardasil } \\ & \mathrm{N}=2717 \\ & (013) \\ & \mathrm{N}=6082 \\ & (015) \\ & \text { Total }=8799 \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total = } 8800 \end{aligned}$ | CIN 2 | Gardasil $\mathrm{N}=2717$ $(013)$ $\mathrm{N}=6082$ $(015)$ Total $=8799$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total }=8800 \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HPV 51 Total | 11 | 13 (3 also naïve for Vax HPV) | HPV 51 Total | 18 | 25 (11 also naïve for Vax HPV) |
| 51 alone | 4 | 2 | 51 alone | 6 | 5 |
| 51, 6, 16 | 0 | 1 | 51, 6 | 0 | 1 |
| 51, 6, 18, 35, 45, | 0 | 1 | 51, 6, 56 | 1 | 0 |
| 52, 56 | 1 (naïve | 1 | 51, 11 | 0 | 1 |
| 51, 16 | for 16) |  | 51, 16 | 0 | 3 |
| 51, 16, 31 | 0 | 1 | 51, 16 | 0 | 1 |
| 51, 16, 31, 52 | 0 | 2 (1 naïve for 16, 1 | 51, 16, 18, 45, 52 | 0 | 1 |
|  |  | naïve for 52) | 51, 16, 33, 39, 52 | 0 | 1 |
| 51, 16, 33, 56 | 0 | 1 | 51, 16, 35 | 0 | 1 |
| 51, 16, 56 | 0 | 1 | 51, 16, 52, 58 | 0 | 1 |
| 51, 18, 31, 58 | 0 | 1 | 51, 18, 31 | 0 | 1 |
| 51, 31, 52 | 0 | 1 | 51, 18, 52 | 0 | 1 |
| 51, 31, 58 | 1 | 0 | 51, 18, 52, 58 | 0 | 1 |
| 51, 33 | 1 | 0 | 51, 31 | 0 | 1 |
| 51, 33, 56 | 1 | 0 | 51, 31, 45 | 0 | 1 |
| 51, 35 | 1 | 0 | 51, 31, 52, 58 | 1 | 0 |
| 51, 39, 56 | 1 | 0 | 51, 31, 59 | 0 | 1 |
| 51, 45, 56 | 0 | 1 | 51, 33, 52 | 1 | 0 |
| 51, 58 | 1 | 0 | 51, 39, 52 | 1 | 0 |
|  |  |  | 51, 52 | 2 | 0 |
|  |  |  | 51, 52, 56, 58 | 1 | 0 |
|  |  |  | 51, 52, 58 | 0 | 2 |
|  |  |  | 51, [52], 59 | 1 | 0 |
|  |  |  | 51, 56 | 3 | 1 |
|  |  |  | 51, 56, 58 | 0 | 1 |
|  |  |  | 51, 59 | 1 | 0 |

HPV types in italics represent $P$ - for the relevant non-vaccine HPV type and other HPV types
Case may appear in more than one table for both CIN 2 and CIN 3 cases.

CIN 3 and CIN 2 Cases associated with Non-Vaccine HPV type 52 and $P$ - at baseline for relevant HPV types (Close-out Data for Studies HPV-013 and HPV-015)

| CIN 3 | $\begin{aligned} & \text { Gardasil } \\ & \mathrm{N}=2717(013) \\ & \mathrm{N}=6082(015) \\ & \text { Total }=8799 \end{aligned}$ | $\begin{aligned} & \hline \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total = } 8800 \end{aligned}$ | CIN 2 | $\begin{aligned} & \text { Gardasil } \\ & \mathrm{N}=2717 \\ & (013) \\ & \mathrm{N}=6082 \\ & (015) \\ & \text { Total }= \\ & 8799 \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total }=8800 \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HPV 52 Total | 18 | 26 (8 also naïve for Vax HPV) | HPV 52 Total | 24 | 25 (6 also naïve for Vax HPV) |
| 52 alone | 7 | 6 | 52 alone | 13 | 6 |
| 52, 16 | 1 | 5 (4 naïve for 16) | 52, 6 | 0 | 1 |
| 52, 16, 18 | 0 | 1 | 52, 6, 31 | 0 | 1 |
| 52, 16, 31, 51 | 0 | 2 | 52, 16 | 0 | 1 |
| 52, 16, 33 | 0 | 1 | 52, 16, 18, 45, 51 | 0 | 1 |
| 52, 16, 39, 58 | 1 | 0 | 52, 16, 33, 39, 51 | 0 | 1 |
| 52, 16, 45 | 0 | 1 | 52, 16, 51, 58 | 0 | 1 |
| 52, 16, 56 | 0 | 3 (2 naïve for 16 and 2 naïve | 52, 18, 51 | 0 | 1 |
|  |  | for 56) | 52, 18, 51, 58 | 0 | 1 |
| 52, 16, 58 | 0 | 1 | 52, 18, 56, 59 | 0 | 1 |
| 52, 31 | 1 | 1 | 52, 31 | 0 | 3 |
| 52, 31, 51 | 0 | 1 | 52; 31 | 0 | 1 |
| 52, 31, 56 | 1 | 0 | 52, 31, 35, 39 | 1 | 0 |
| 52, 31, 58 | 0 | 1 | 52, 31, 51, 58 | 1 | 0 |
| 52, 31, 59 | 1 | 0 | 52, 33, 39, 45 | 0 | 1 |
| 52, 33 | 1 (naïve for | 1 | 52, 33, 51 | 1 | 0 |
|  | 33) |  | [52], 33, 56 | 1 | 0 |
| 52, 39 | 1 | 0 | 52, 39 | 0 | 1 |
| 52, 45 | 0 | 1 | 52, 39, 51 | 1 | 0 |
| 52, 51 | 1 | 1 | 52, 39, 56 | 0 | 1 |
| 52, 51, 56 | 1 | 0 | 52, 45, 56, 58 | 1 | 0 |
| 52, 58 | 1 | 0 | 52, 51 | 2 | 0 |
| 52, 59 | 1 | 0 | 52, 51, 58 | 0 | 2 |
|  |  |  | [52], 51, 59 | 1 | 0 |
|  |  |  | 52, 56 | 0 | 1 |
|  |  |  | 52, 58 | 1 | 0 |
|  |  |  | 52, 58, 59 | 1 | 0 |

HPV types in italics represent $P$-for the relevant non-vaccine HPV type and other HPV types
Case may appear in more than one table for both CIN 2 and CIN 3 cases.

CIN 3 and CIN 2 Cases associated with Non-Vaccine HPV type 56 and $P$ - at baseline for relevant HPV types (Close-out Data for Studies HPV-013 and HPV-015)

| CIN 3 | $\begin{aligned} & \text { Gardasil } \\ & \mathrm{N}=2717 \\ & (013) \\ & \mathrm{N}=6082 \\ & (015) \\ & \text { Total }=8799 \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total }=8800 \end{aligned}$ | CIN 2 | $\begin{aligned} & \text { Gardasil } \\ & \mathrm{N}=2717(013) \\ & \mathrm{N}=6082(015) \\ & \text { Total }=8799 \end{aligned}$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total }=8800 \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HPV 56 Total | 9 | 16 (7 also naïve for Vax HPV) | HPV 56 Total | 21 | 16 (6 also naïve for Vax HPV) |
| 56 alone | 1 | 1 | 56 alone | 8 | 1 |
| 56, 6, 18, 35, 45, 51 | 0 | 1 | 56, 16 | 0 | 2 |
| 56, 11, 16 | 0 | 1 | 56, 16, 31, 58 | 0 | 1 |
| 56, 11, 16, 18, 51, 58 | 0 | 1 | 56, 18 | 0 | 2 |
| 56, 16 | 2 | 1 (naïve for 16) | 56, 18, 33 | 0 | 1 |
| 56, 16, 18 | 0 | 1 | 56, 18, 52, 59 | 0 | 1 |
| 56, 16, 31, 58, 59 | 0 | 1 | 56, 31 | 0 | 1 |
| 56, 16, 33, 51 | 0 | 1 | 56, 33 | 5 | 1 |
| 56, 16, 35 | 0 | 1 | 56, 33, [52] | 1 | 0 |
| 56, 16, 51 | 0 | 1 | 56, 35, 39 | 1 | 0 |
| 56, 16, 52 | 0 | 2 | 56, 39 | 1 | 0 |
| 56, 31, 33, 51 | 1 | 0 | 56, 39, 52 | 0 | 1 |
| 56, 31, 58 | 1 | 0 | 56, 51 | 3 | 1 |
| 56, 33 | 1 | 0 | 56, 51, 52, 58 | 1 | 0 |
| 56, 33, 58 | 0 | 1 | 56, 51, 58 | 0 | 1 |
| 56, 45 | 1 | 0 | 56, 52 | 0 | 1 |
| 56, 45, 51 | 0 | 1 | 56, 58 | 1 | 1 |
| 56, 51, 33 | 1 | 0 | 56, 59 | 0 | 1 |
| 56, 51, 39 | 1 | 0 |  |  |  |
| 56, 58 | 0 | 2 |  |  |  |

18 above indicates serology below cutoff but not undetectable
HPV types in italics represent P-for the relevant non-vaccine HPV type and other HPV types
Case may appear in more than one table for both CIN 2 and CIN 3 cases.

CIN 3 and CIN 2 Cases associated with Non-Vaccine HPV type 58 and P- at baseline for relevant HPV types (Close-out Data for Studies HPV-013 and HPV-015)

| CIN 3 | $\begin{aligned} & \hline \text { Gardasil } \\ & \mathrm{N}=2717 \\ & \text { (013) } \\ & \mathrm{N}=6082 \\ & \text { (015) } \\ & \text { Total = } \\ & 8799 \\ & \hline \end{aligned}$ | Control $\mathrm{N}=2725$ (013) $\mathrm{N}=6075$ (015) Total $=8800$ | CIN 2 | Gardasil $\mathrm{N}=2717$ (013) $\mathrm{N}=6082(015)$ Total $=8799$ | Control $\mathrm{N}=2725$ (013) $\mathrm{N}=6075$ (015) Total $=8800$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HPV 58 Total | 8 | 16 (5 also naïve for Vax HPV) | HPV 58 Total | 12 | 17 (6 also naïve for Vax HPV) |
| 58 alone | 4 | 4 | 58 alone | 6 | 6 |
| 58, 6 | 0 | 1 | 58, 6 | 0 | 1 |
| $\begin{aligned} & 58,11,16,18,51, \\ & 56 \end{aligned}$ | 0 | 1 | $\begin{aligned} & 58,16,31,33, \\ & 45 \end{aligned}$ | 0 | 1 |
| 58, 16 | 0 | 1 | 58, 16, 18, 31, | 0 | 1 |
| 58, 16, 31, 33 | 0 | 1 | 56 |  |  |
| 58, 16, 31, 56, 59 | 0 | 1 | 58, 16, 51, 52 | 0 | 1 |
| 58, 16, 56 | 0 | 1 | 58, 18, 51, 52 | 0 | 1 |
| 58, 18, 31, 51 | 0 | 1 | 58, 31 | 0 | 1 |
| 58, 31, 51 | 1 | 0 | 58, 33 | 1 | 0 |
| 58, 31, 52 | 0 | 1 | 58, 39 | 1 | 1 |
| 58, 31, 56 | 1 | 0 | 58, 51, 52 | 0 | 2 |
| 58, 33, 56 | 0 | 1 | 58, 51, 52, 56 | 1 | 0 |
| 58, 51 | 1 | 0 | 58, 51, 56 | 0 | 1 |
| 58, 52 | 1 | 0 | 58, 52 | 1 | 0 |
| 58, 56 | 0 | 2 | 58, 52, 59 | 1 | 0 |
| 58, 59 | 0 | 1 | 58, 56 | 1 | 1 |

18 above indicates serology below cutoff but not undetectable
HPV types in italics represent P-for the relevant non-vaccine HPV type and other HPV types
Case may appear in more than one table for both CIN 2 and CIN 3 cases.

CIN 3 Cases and CIN 2 Cases associated with Non-Vaccine HPV type 59 and P- at baseline for relevant HPV types (Close-out Data for Studies HPV-013 and HPV-015)

| CIN 3 | Gardasil $\mathrm{N}=2717$ $(013)$ $\mathrm{N}=6082$ $(015)$ Total $=$ 8799 | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total }=8800 \end{aligned}$ | CIN 2 | Gardasil $\mathrm{N}=2717$ $(013)$ $\mathrm{N}=6082$ (015) Total $=8799$ | $\begin{aligned} & \text { Control } \\ & \mathrm{N}=2725(013) \\ & \mathrm{N}=6075(015) \\ & \text { Total }=8800 \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HPV 59 Total | 6 | 6 (3 also naïve for Vax HPV) | HPV 59 Total | 3 | 7 (3 also naïve for Vax HPV) |
| 59 alone | 2 | 0 | 59 alone | 0 | 1 |
| 59, 16 | 0 | 3 (2 naïve for 16) | 59, 16 | 0 | 1 |
| 59, 16, 31, 56, | 0 | 1 | 59, 18 | 0 | 1 |
| 58 |  |  | 59, 18, 52, 56 | 0 | 1 |
| 59, 31 | 1 | 0 | 59, 31 | 1 | 1 |
| 59, 31, 52 | 1 | 0 | 59, 31, 51 | 0 | 1 |
| 59, 33 | 1 | 0 | 59, 51 | 1 | 0 |
| 59, 33, 39 | 0 | 1 | 59, 51, [52] | 1 | 0 |
| 59, 52 | 1 | 0 | 59, 56 | 0 | 1 |
| 59, 58 | 0 | 1 | 59, 52, 58 | 1 | 0 |

HPV types in italics represent $P$-for the relevant non-vaccine HPV type and other HPV types
Case may appear in more than one table for both CIN 2 and CIN 3 cases.

